Latest News

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer’s Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying

Jan. 16, 2014, 3:20 a.m. EST Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer’s Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying Study indicates potential for TauC3 to be disease-modifying.   ENGLEWOOD CLIFFS, N.J., Jan 16, 2014 (GLOBE NEWSWIRE via COMTEX) — [...]

FDA Panel Backs Blood Pressure Drug (Northera) for Parkinson’s Patients

http://www.dddmag.com/news/2014/01/fda-panel-backs-blood-pressure-drug-parkinsons-patients?et_cid=3712933&et_rid=474801240&location=top FDA Panel Backs Blood Pressure Drug (Northera) for Parkinson’s Patients A panel of federal experts recommended approval for Chelsea Therapeutics’ experimental blood pressure drug Northera, which is designed to prevent dizziness and fainting in Parkinson’s disease patients. The Food and Drug Administration’s panel of outside experts voted 16-1 on Tuesday in favor of approving [...]

Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery

Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery SAN FRANCISCO, Jan. 14, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has completed the in-licensure of Eltoprazine from PGI [...]

AGREEMENT WITH THE ROSKAMP INSTITUTE TO ADVANCE THE CLINICAL DEVELOPMENT OF ANAVEX PLUS (ANAVEX 2-73 plus donepezil)

AGREEMENT WITH THE ROSKAMP INSTITUTE TO ADVANCE THE CLINICAL DEVELOPMENT OF ANAVEX PLUS (ANAVEX 2-73 plus donepezil) NEW YORK, NY – January 13, 2014 –  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a [...]

Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277

Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277 Results Support Expected 505(b)2 Path to New Drug Application (NDA) in the United States TORONTO, CANADA–(Marketwired – Jan 13, 2014) – Cynapsus Therapeutics Inc. (TSX VENTURE:CTH) (CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer [...]

XenoPort Provides Updates on XP23829 Development and HORIZANT Performance Highlights

XenoPort Provides Updates on XP23829 Development and HORIZANT Performance Highlights SANTA CLARA, Calif.–(BUSINESS WIRE)– XenoPort (XNPT) today reported an update on XP23289 development, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and XenoPort’s progress on commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets. XenoPort reported today that it received feedback [...]

Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704 (memantine/donepezil combination)

Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704 (memantine/donepezil combination) EMERYVILLE, Calif., Jan. 9, 2014 /PRNewswire/ – Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited (FRX) for MDX-8704.  MDX-8704 is a fixed dosed combination (FDC) of Namenda XR® (memantine HCl [...]

Gel reduced daily tremors in Parkinson’s disease

http://www.uab.edu/news/latest/item/4019-gel-reduced-daily-tremors-in-parkinsons-disease Friday, January 03, 2014 Gel reduced daily tremors in Parkinson’s disease By Bob Shepard An experimental treatment for Parkinson’s disease reduced by nearly two hours on average the period each day when medication failed to control patients’ slowness and shaking, according to results from a double-blind, phase III clinical trial published in December 2013, [...]

Antioxidant drug knocks down multiple sclerosis-like disease in mice

Antioxidant drug knocks down multiple sclerosis-like disease in mice 12/26/13  Portland, Ore. Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease. The antioxidant — called MitoQ — [...]

Alkermes Gets US Patent for Novel MS Prodrug

http://www.dddmag.com/news/2014/01/alkermes-gets-us-patent-novel-ms-prodrug?et_cid=3697034&et_rid=474801240&location=top Alkermes Gets US Patent for Novel MS Prodrug Tue, 01/07/2014 – 9:34am Alkermes plc announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 14/032,736, entitled “Prodrugs of fumarates and their use in treating various diseases.” The allowed composition of matter claims will cover [...]

Page 1 of 15612345...102030...Last »